AU6409799A - Tissue analysis and kits therefor - Google Patents

Tissue analysis and kits therefor

Info

Publication number
AU6409799A
AU6409799A AU64097/99A AU6409799A AU6409799A AU 6409799 A AU6409799 A AU 6409799A AU 64097/99 A AU64097/99 A AU 64097/99A AU 6409799 A AU6409799 A AU 6409799A AU 6409799 A AU6409799 A AU 6409799A
Authority
AU
Australia
Prior art keywords
tissue analysis
kits therefor
kits
therefor
tissue
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU64097/99A
Inventor
Robert L. Cohen
Mary Beth Gardiner
Mark X. Sliwkowski
Gregory T. Stelzer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CYTOMETRY ASSOCIATES
Genentech Inc
Original Assignee
Cytometry Ass
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cytometry Ass, Genentech Inc filed Critical Cytometry Ass
Publication of AU6409799A publication Critical patent/AU6409799A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6841—In situ hybridisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/582—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6804—Nucleic acid analysis using immunogens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators
AU64097/99A 1998-10-07 1999-10-01 Tissue analysis and kits therefor Abandoned AU6409799A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/167,691 US6573043B1 (en) 1998-10-07 1998-10-07 Tissue analysis and kits therefor
US09167691 1998-10-07
PCT/US1999/022909 WO2000020641A1 (en) 1998-10-07 1999-10-01 Tissue analysis and kits therefor

Publications (1)

Publication Number Publication Date
AU6409799A true AU6409799A (en) 2000-04-26

Family

ID=22608409

Family Applications (1)

Application Number Title Priority Date Filing Date
AU64097/99A Abandoned AU6409799A (en) 1998-10-07 1999-10-01 Tissue analysis and kits therefor

Country Status (3)

Country Link
US (7) US6573043B1 (en)
AU (1) AU6409799A (en)
WO (1) WO2000020641A1 (en)

Families Citing this family (165)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0878552A1 (en) * 1997-05-13 1998-11-18 Erasmus Universiteit Rotterdam Molecular detection of chromosome aberrations
WO1999057309A1 (en) * 1998-05-04 1999-11-11 Dako A/S Method and probes for the detection of chromosome aberrations
US20030086924A1 (en) * 1999-06-25 2003-05-08 Genentech, Inc. Treatment with anti-ErbB2 antibodies
US6949245B1 (en) * 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
US20040013667A1 (en) * 1999-06-25 2004-01-22 Genentech, Inc. Treatment with anti-ErbB2 antibodies
EP1280923A2 (en) * 2000-04-28 2003-02-05 Millennium Pharmaceuticals, Inc. 14094, a human trypsin family member and uses thereof
JP2003534292A (en) * 2000-05-19 2003-11-18 ジェネンテック・インコーポレーテッド ERBB antagonist gene detection assays to increase the likelihood of effective response to cancer treatment
US7128903B2 (en) 2001-10-03 2006-10-31 Innovative Pharmaceutical Concepts (Ipc) Inc. Pharmaceutical preparations useful for treating tumors and lesions of the skin and the mucous membranes and methods and kits using same
AU2002353443A1 (en) * 2001-11-07 2003-05-19 Bioview Ltd. Kits and methods for preparing cell samples optimized for dual staining
US20040229294A1 (en) 2002-05-21 2004-11-18 Po-Ying Chan-Hui ErbB surface receptor complexes as biomarkers
US7402397B2 (en) 2002-05-21 2008-07-22 Monogram Biosciences, Inc. Detecting and profiling molecular complexes
US20040229380A1 (en) * 2002-05-21 2004-11-18 Po-Ying Chan-Hui ErbB heterodimers as biomarkers
US20050037406A1 (en) * 2002-06-12 2005-02-17 De La Torre-Bueno Jose Methods and apparatus for analysis of a biological specimen
US7272252B2 (en) * 2002-06-12 2007-09-18 Clarient, Inc. Automated system for combining bright field and fluorescent microscopy
ES2428941T3 (en) * 2003-03-10 2013-11-12 Expression Pathology, Inc. Liquid tissue preparation from biological samples, tissues and cells histopathologically processed
US8062897B2 (en) 2003-07-21 2011-11-22 Aureon Laboratories, Inc. Diagnostic histopathology using multiplex gene expression FISH
WO2005037071A2 (en) * 2003-10-14 2005-04-28 Monogram Biosciences, Inc. Receptor tyrosine kinase signaling pathway analysis for diagnosis and therapy
JO3000B1 (en) 2004-10-20 2016-09-05 Genentech Inc Antibody Formulations.
US20060115862A1 (en) * 2004-11-17 2006-06-01 Duke University Anti-tenascin monoclonal antibody immunoassays and diagnostic kits
CN101115849A (en) * 2004-12-07 2008-01-30 健泰科生物技术公司 Selecting patients for therapy with a her inhibitor
US7449184B2 (en) 2005-01-21 2008-11-11 Genentech, Inc. Fixed dosing of HER antibodies
AU2006213659A1 (en) * 2005-02-09 2006-08-17 Genentech, Inc. Inhibiting HER2 shedding with matrix metalloprotease antagonists
PT1850874E (en) * 2005-02-23 2013-12-02 Genentech Inc Extending time to disease progression or survival in ovarian cancer patients using pertuzumab
WO2006096861A2 (en) * 2005-03-08 2006-09-14 Genentech, Inc. METHODS FOR IDENTIFYING TUMORS RESPONSIVE TO TREATMENT WITH HER DIMERIZATION INHIBITORS (HDIs)
JP2006316040A (en) 2005-05-13 2006-11-24 Genentech Inc Herceptin(r) adjuvant treatment
PE20070207A1 (en) * 2005-07-22 2007-03-09 Genentech Inc COMBINED TREATMENT OF TUMORS THAT EXPRESS HER
US9957569B2 (en) * 2005-09-12 2018-05-01 The Regents Of The University Of Michigan Recurrent gene fusions in prostate cancer
CA2814598A1 (en) * 2005-09-12 2007-03-22 The Regents Of The University Of Michigan Recurrent gene fusions in prostate cancer
US8497258B2 (en) 2005-11-12 2013-07-30 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
US20120208824A1 (en) 2006-01-20 2012-08-16 Cell Signaling Technology, Inc. ROS Kinase in Lung Cancer
US20080032321A1 (en) * 2006-08-07 2008-02-07 General Electric Company System and methods for analyzing images of tissue samples
US8131476B2 (en) * 2006-08-07 2012-03-06 General Electric Company System and method for co-registering multi-channel images of a tissue micro array
US8060348B2 (en) * 2006-08-07 2011-11-15 General Electric Company Systems for analyzing tissue samples
US7629125B2 (en) 2006-11-16 2009-12-08 General Electric Company Sequential analysis of biological samples
US7741045B2 (en) * 2006-11-16 2010-06-22 General Electric Company Sequential analysis of biological samples
US9201063B2 (en) * 2006-11-16 2015-12-01 General Electric Company Sequential analysis of biological samples
US8305579B2 (en) * 2006-11-16 2012-11-06 Thomas Pirrie Treynor Sequential analysis of biological samples
PE20090681A1 (en) 2007-03-02 2009-06-10 Genentech Inc PREDICTION OF RESPONSE TO A HER INHIBITOR
US9551033B2 (en) * 2007-06-08 2017-01-24 Genentech, Inc. Gene expression markers of tumor resistance to HER2 inhibitor treatment
CA2690334C (en) 2007-06-08 2017-02-14 Genentech, Inc. Gene expression markers of tumor resistance to her2 inhibitor treatment
CA2814246A1 (en) 2007-07-06 2009-01-15 The Regents Of The University Of Michigan Solute carrier family 45 member 3 (slc45a3) and erg family gene fusions in prostate cancer
AU2008275303B2 (en) * 2007-07-06 2012-05-03 The Regents Of The University Of Michigan MIPOL1-ETV1 gene rearrangements
TWI472339B (en) 2008-01-30 2015-02-11 Genentech Inc Composition comprising antibody that binds to domain ii of her2 and acidic variants thereof
US20110110923A1 (en) * 2008-02-12 2011-05-12 The Brigham And Women's Hospital, Inc. Fish assay for eml4 and alk fusion in lung cancer
WO2009117138A2 (en) * 2008-03-21 2009-09-24 Spring Bioscience Corporation Counterstaining method for dual-stain in situ hybridization
US20090304714A1 (en) * 2008-03-25 2009-12-10 The Regents Of The University Of Michigan IKKi Inhibitor Therapies and Screening Methods, and Related IKKi Diagnostics
AU2009253675A1 (en) 2008-05-28 2009-12-03 Genomedx Biosciences, Inc. Systems and methods for expression-based discrimination of distinct clinical disease states in prostate cancer
BRPI0812682A2 (en) 2008-06-16 2010-06-22 Genentech Inc metastatic breast cancer treatment
ES2538123T3 (en) * 2008-08-22 2015-06-17 Ventana Medical Systems, Inc. Method for chromogenic detection of two or more target molecules in a single sample
JP2012514475A (en) 2009-01-09 2012-06-28 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン Reproducible gene fusions in cancer
CA2744236C (en) 2009-02-12 2021-03-16 Cell Signaling Technology, Inc. Mutant ros expression in human cancer
ES2572728T3 (en) 2009-03-20 2016-06-02 F. Hoffmann-La Roche Ag Bispecific anti-HER antibodies
US8741581B2 (en) 2009-04-27 2014-06-03 Technion Research And Development Foundation Ltd. Markers for cancer detection
JP5705836B2 (en) 2009-05-29 2015-04-22 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト Modulators for HER2 signaling in gastric cancer patients expressing HER2
CN104945509A (en) 2009-09-16 2015-09-30 弗·哈夫曼-拉罗切有限公司 Coiled coil and/or tether containing protein complexes and uses thereof
WO2011034906A2 (en) 2009-09-17 2011-03-24 The Regents Of The University Of Michigan Recurrent gene fusions in prostate cancer
FR2950360B1 (en) * 2009-09-22 2011-11-25 Centre Nat Rech Scient CELL IMAGING METHOD FOR VISUALIZATION OF MICROARN BIOGENESIS IN CELLS
US9677125B2 (en) * 2009-10-21 2017-06-13 General Electric Company Detection of plurality of targets in biological samples
US9556249B2 (en) 2010-02-18 2017-01-31 Genentech, Inc. Neuregulin antagonists and use thereof in treating cancer
US8609354B2 (en) 2010-03-04 2013-12-17 Olli CARPEN Method for selecting patients for treatment with an EGFR inhibitor
TW201138821A (en) 2010-03-26 2011-11-16 Roche Glycart Ag Bispecific antibodies
US10787701B2 (en) 2010-04-05 2020-09-29 Prognosys Biosciences, Inc. Spatially encoded biological assays
PT2556171E (en) 2010-04-05 2015-12-21 Prognosys Biosciences Inc Spatially encoded biological assays
US20190300945A1 (en) 2010-04-05 2019-10-03 Prognosys Biosciences, Inc. Spatially Encoded Biological Assays
US8383793B2 (en) 2010-04-15 2013-02-26 St. Jude Children's Research Hospital Methods and compositions for the diagnosis and treatment of cancer resistant to anaplastic lymphoma kinase (ALK) kinase inhibitors
WO2011146568A1 (en) 2010-05-19 2011-11-24 Genentech, Inc. Predicting response to a her inhibitor
DK2591363T3 (en) 2010-07-07 2017-12-11 Univ Michigan Regents DIAGNOSIS AND TREATMENT OF BREAST CANCER
US20120101108A1 (en) 2010-08-06 2012-04-26 Cell Signaling Technology, Inc. Anaplastic Lymphoma Kinase In Kidney Cancer
US9005907B2 (en) 2010-10-01 2015-04-14 St. Jude Children's Research Hospital Methods and compositions for typing molecular subgroups of medulloblastoma
WO2012058638A2 (en) 2010-10-29 2012-05-03 President And Fellows Of Harvard College Nucleic acid nanostructure barcode probes
JP5916991B2 (en) * 2010-11-09 2016-05-11 オリンパス株式会社 Methods for analyzing genetically abnormal cells
US8945556B2 (en) 2010-11-19 2015-02-03 The Regents Of The University Of Michigan RAF gene fusions
CA2818486C (en) 2010-11-19 2018-09-11 The Regents Of The University Of Michigan Ncrna and uses thereof
US20130245233A1 (en) 2010-11-24 2013-09-19 Ming Lei Multispecific Molecules
EP2655413B1 (en) 2010-12-23 2019-01-16 F.Hoffmann-La Roche Ag Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery
ES2659763T3 (en) 2011-02-14 2018-03-19 The Regents Of The University Of Michigan Compositions and procedures for the treatment of obesity and related disorders
GB201106254D0 (en) 2011-04-13 2011-05-25 Frisen Jonas Method and product
MX2014001354A (en) 2011-08-02 2014-10-14 Pfizer Crizotinib for use in the treatment of cancer.
KR20140057326A (en) 2011-08-17 2014-05-12 제넨테크, 인크. Neuregulin antibodies and uses thereof
JP5812095B2 (en) * 2011-09-09 2015-11-11 コニカミノルタ株式会社 Biological substance detection method
HUE044352T2 (en) 2011-10-14 2019-10-28 Hoffmann La Roche Pertuzumab, trastuzumab, docetaxel and carboplatin for the treatment of early-stage breast cancer
WO2013063229A1 (en) 2011-10-25 2013-05-02 The Regents Of The University Of Michigan Her2 targeting agent treatment in non-her2-amplified cancers having her2 expressing cancer stem cells
JP2014533100A (en) 2011-11-04 2014-12-11 オスロ ウニヴェルスィテーツスィーケフース ハーエフＯｓｌｏ Ｕｎｉｖｅｒｓｉｔｅｔｓｓｙｋｅｈｕｓ Ｈｆ Methods and biomarkers for the analysis of colorectal cancer
RU2019103083A (en) 2011-11-30 2019-03-22 Дженентек, Инк. Mutations of ErbB3 in Cancer
US9376715B2 (en) 2011-12-09 2016-06-28 Roche Molecular Systems, Inc Methods for detecting mutations in the catalytic subunit of the phosphoinositol-3 kinase (PIK3CA) gene
US8568991B2 (en) 2011-12-23 2013-10-29 General Electric Company Photoactivated chemical bleaching of dyes
US9176032B2 (en) 2011-12-23 2015-11-03 General Electric Company Methods of analyzing an H and E stained biological sample
JP2015503923A (en) 2012-01-09 2015-02-05 オスロ ウニヴェルスィテーツスィーケフース ハーエフＯｓｌｏ Ｕｎｉｖｅｒｓｉｔｅｔｓｓｙｋｅｈｕｓ Ｈｆ Methods and biomarkers for the analysis of colorectal cancer
BR112014019579A2 (en) 2012-02-10 2019-10-15 Genentech, Inc SINGLE CHAIN ANTIBODY, POLYNUCLEOTIDE, VECTOR, HOST CELL, METHOD OF PRODUCTION OF A SINGLE CHAIN ANTIBODY, HETEROMULTYMER AND METHOD OF PRODUCTION
CN104220876A (en) 2012-02-21 2014-12-17 奥斯陆大学医院 Methods and biomarkers for detection and prognosis of cervical cancer
EP2823059A2 (en) 2012-03-06 2015-01-14 Oslo Universitetssykehus HF Gene signatures associated with efficacy of postmastectomy radiotherapy in breast cancer
CN102607930A (en) * 2012-03-13 2012-07-25 中国水产科学研究院黑龙江水产研究所 Fish germ cell orientated embedding technology
EP2831115A1 (en) 2012-03-27 2015-02-04 F. Hoffmann-La Roche AG Diagnosis and treatments relating to her3 inhibitors
SI2838998T1 (en) 2012-04-18 2018-04-30 Cell Signaling Technology, Inc. Egfr and ros1 in cancer
WO2014001326A1 (en) 2012-06-27 2014-01-03 F. Hoffmann-La Roche Ag Method for the selection and production of tailor-made, selective and multi-specific therapeutic molecules comprising at least two different targeting entities and uses thereof
RU2639287C2 (en) 2012-06-27 2017-12-20 Ф. Хоффманн-Ля Рош Аг Method for selection and obtaining of highly selective and multispecific targeting groups with specified properties, including at least two different binding groups, and their applications
WO2014001325A1 (en) 2012-06-27 2014-01-03 F. Hoffmann-La Roche Ag Method for making antibody fc-region conjugates comprising at least one binding entity that specifically binds to a target and uses thereof
EP4219765A3 (en) 2012-08-16 2023-09-20 Decipher Biosciences, Inc. Prostate cancer prognosis using biomarkers
US10093740B2 (en) 2012-10-15 2018-10-09 Universitat Zurich Bispecific HER2 ligands for cancer therapy
EP2719706A1 (en) 2012-10-15 2014-04-16 Universität Zürich Bispecific HER2 ligands for cancer therapy
EP2909341A2 (en) 2012-10-18 2015-08-26 Oslo Universitetssykehus HF Biomarkers for cervical cancer
BR112015012644A2 (en) 2012-11-30 2017-12-19 Hoffmann La Roche method for determining a cancer patient's need, cancer treatment method, pharmaceutical composition, use of a nucleic acid or antibody and kit;
US9135694B2 (en) 2012-12-04 2015-09-15 General Electric Company Systems and methods for using an immunostaining mask to selectively refine ISH analysis results
US9915592B2 (en) 2013-03-06 2018-03-13 General Electric Company Methods of analyzing an H and E stained biological sample
NZ712012A (en) 2013-04-16 2020-04-24 Genentech Inc Pertuzumab variants and evaluation thereof
US20160067307A1 (en) 2013-05-01 2016-03-10 Five Prime Therapeutics, Inc. Methods of treating cancer
WO2014179734A1 (en) 2013-05-02 2014-11-06 The Regents Of The University Of Michigan Deuterated amlexanox
US9879313B2 (en) 2013-06-25 2018-01-30 Prognosys Biosciences, Inc. Methods and systems for determining spatial patterns of biological targets in a sample
EP3696277B1 (en) 2013-07-30 2023-01-25 President and Fellows of Harvard College Quantitative dna-based imaging and super-resolution imaging
AU2015220749B2 (en) 2014-02-21 2020-12-24 Ventana Medical Systems, Inc. Single-stranded oligonucleotide probes for chromosome or gene copy enumeration
CA2932943C (en) 2014-03-11 2023-09-26 President And Fellows Of Harvard College High-throughput and highly multiplexed imaging with programmable nucleic acid probes
JP6696908B2 (en) 2014-04-25 2020-05-20 エグゼリクシス， インコーポレイテッド How to treat lung adenocarcinoma
KR20160141857A (en) 2014-04-25 2016-12-09 제넨테크, 인크. Methods of treating early breast cancer with trastuzumab-mcc-dm1 and pertuzumab
ES2764111T3 (en) 2014-12-03 2020-06-02 Hoffmann La Roche Multispecific antibodies
CN113186256A (en) 2015-04-10 2021-07-30 空间转录公司 Spatially differentiated, multiplexed nucleic acid analysis of biological samples
CN107614015A (en) 2015-05-30 2018-01-19 豪夫迈·罗氏有限公司 Treat HER2 positives Locally Advanced or the previously method of untreated metastatic breast cancer
WO2016196478A1 (en) 2015-06-01 2016-12-08 St. Jude Children's Research Hospital Methods and compositions for prognostications and/or clinical management of graft-versus-host disease and transplant rejection
KR20170007181A (en) 2015-07-10 2017-01-18 3스캔 인크. Spatial multiplexing of histological stains
KR102557419B1 (en) 2015-08-07 2023-07-19 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 Super-resolution imaging of protein-protein interactions
WO2017087280A1 (en) 2015-11-16 2017-05-26 Genentech, Inc. Methods of treating her2-positive cancer
WO2017132538A1 (en) 2016-01-29 2017-08-03 The Regents Of The University Of Michigan Amlexanox analogs
EP3454863A1 (en) 2016-05-10 2019-03-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Combinations therapies for the treatment of cancer
WO2018039490A1 (en) 2016-08-24 2018-03-01 Genomedx Biosciences, Inc. Use of genomic signatures to predict responsiveness of patients with prostate cancer to post-operative radiation therapy
CA3040913A1 (en) 2016-11-04 2018-05-11 Genentech, Inc. Treatment of her2-positive breast cancer
EP3551765A4 (en) 2016-12-09 2020-11-11 Ultivue, Inc. Improved methods for multiplex imaging using labeled nucleic acid imaging agents
KR102313262B1 (en) 2016-12-28 2021-10-14 제넨테크, 인크. Treatment of advanced HER2-expressing cancer
WO2018127786A1 (en) 2017-01-06 2018-07-12 Oslo Universitetssykehus Hf Compositions and methods for determining a treatment course of action
TWI729259B (en) 2017-01-17 2021-06-01 美商建南德克公司 Subcutaneous her2 antibody formulations
US11208697B2 (en) 2017-01-20 2021-12-28 Decipher Biosciences, Inc. Molecular subtyping, prognosis, and treatment of bladder cancer
HUE064898T2 (en) 2017-03-02 2024-04-28 Genentech Inc Adjuvant treatment of her2-positive breast cancer
EP3593140A4 (en) 2017-03-09 2021-01-06 Decipher Biosciences, Inc. Subtyping prostate cancer to predict response to hormone therapy
TW201902509A (en) 2017-04-24 2019-01-16 美商建南德克公司 ERBB2/HER2 mutation
CA3062716A1 (en) 2017-05-12 2018-11-15 Decipher Biosciences, Inc. Genetic signatures to predict prostate cancer metastasis and identify tumor agressiveness
CN107917832A (en) * 2017-12-04 2018-04-17 山西农业大学 The production method of fish ovary tissue paraffin section
BR112020021218A2 (en) 2018-04-18 2021-03-02 St. Jude Children's Research Hospital genotyping assays to identify mutations in xaf1
US11519033B2 (en) 2018-08-28 2022-12-06 10X Genomics, Inc. Method for transposase-mediated spatial tagging and analyzing genomic DNA in a biological sample
JP2022504472A (en) 2018-10-08 2022-01-13 ウニベルシテート チューリッヒ HER2-binding tetrameric polypeptide
EP3894590A2 (en) 2018-12-10 2021-10-20 10X Genomics, Inc. Methods of using master / copy arrays for spatial detection
US11926867B2 (en) 2019-01-06 2024-03-12 10X Genomics, Inc. Generating capture probes for spatial analysis
US11649485B2 (en) 2019-01-06 2023-05-16 10X Genomics, Inc. Generating capture probes for spatial analysis
WO2020243579A1 (en) 2019-05-30 2020-12-03 10X Genomics, Inc. Methods of detecting spatial heterogeneity of a biological sample
EP4025711A2 (en) 2019-11-08 2022-07-13 10X Genomics, Inc. Enhancing specificity of analyte binding
FI3891300T3 (en) 2019-12-23 2023-05-10 10X Genomics Inc Methods for spatial analysis using rna-templated ligation
US11732299B2 (en) 2020-01-21 2023-08-22 10X Genomics, Inc. Spatial assays with perturbed cells
US11702693B2 (en) 2020-01-21 2023-07-18 10X Genomics, Inc. Methods for printing cells and generating arrays of barcoded cells
US11898205B2 (en) 2020-02-03 2024-02-13 10X Genomics, Inc. Increasing capture efficiency of spatial assays
US11732300B2 (en) 2020-02-05 2023-08-22 10X Genomics, Inc. Increasing efficiency of spatial analysis in a biological sample
US11891654B2 (en) 2020-02-24 2024-02-06 10X Genomics, Inc. Methods of making gene expression libraries
ES2965354T3 (en) 2020-04-22 2024-04-12 10X Genomics Inc Methods for spatial analysis using targeted RNA deletion
WO2021236929A1 (en) 2020-05-22 2021-11-25 10X Genomics, Inc. Simultaneous spatio-temporal measurement of gene expression and cellular activity
AU2021275906A1 (en) 2020-05-22 2022-12-22 10X Genomics, Inc. Spatial analysis to detect sequence variants
WO2021242834A1 (en) 2020-05-26 2021-12-02 10X Genomics, Inc. Method for resetting an array
WO2021252499A1 (en) 2020-06-08 2021-12-16 10X Genomics, Inc. Methods of determining a surgical margin and methods of use thereof
EP4165207A1 (en) 2020-06-10 2023-04-19 10X Genomics, Inc. Methods for determining a location of an analyte in a biological sample
AU2021294334A1 (en) 2020-06-25 2023-02-02 10X Genomics, Inc. Spatial analysis of DNA methylation
US11761038B1 (en) 2020-07-06 2023-09-19 10X Genomics, Inc. Methods for identifying a location of an RNA in a biological sample
WO2022011276A1 (en) * 2020-07-09 2022-01-13 Axon Imaging, Llc Advanced nervous tissue imaging system
CN112014187A (en) * 2020-09-07 2020-12-01 四川大学华西医院 Preparation method of section of non-decalcified osteochondral tissue and cell tracing and RNAscope combined testing method thereof
US11926822B1 (en) 2020-09-23 2024-03-12 10X Genomics, Inc. Three-dimensional spatial analysis
US11827935B1 (en) 2020-11-19 2023-11-28 10X Genomics, Inc. Methods for spatial analysis using rolling circle amplification and detection probes
WO2022140028A1 (en) 2020-12-21 2022-06-30 10X Genomics, Inc. Methods, compositions, and systems for capturing probes and/or barcodes
WO2022221637A1 (en) * 2021-04-16 2022-10-20 Advanced Cell Diagnostics, Inc. Methods and compositions for reducing autofluorescence
WO2023021330A1 (en) 2021-08-16 2023-02-23 University Of Oslo Compositions and methods for determining a treatment course of action
WO2023034489A1 (en) 2021-09-01 2023-03-09 10X Genomics, Inc. Methods, compositions, and kits for blocking a capture probe on a spatial array
WO2023152568A2 (en) 2022-02-10 2023-08-17 Oslo Universitetssykehus Hf Compositions and methods for characterizing lung cancer

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4968603A (en) 1986-12-31 1990-11-06 The Regents Of The University Of California Determination of status in neoplastic disease
US5843640A (en) 1992-06-19 1998-12-01 Northwestern University Method of simultaneously detecting amplified nucleic acid sequences and cellular antigens in cells
WO1994000764A1 (en) 1992-06-26 1994-01-06 THE UNITED STATES OF AMERICA, represented by THE SECRETARY OF HEALTH AND HUMAN SERVICES The met proto-oncogene and a method for predicting breast cancer progression
WO1994009022A1 (en) 1992-10-09 1994-04-28 Oncor, Inc. Methods for the detection of chromosome structural abnormalities by in situ hybridization to fixed tissue
US5801005A (en) * 1993-03-17 1998-09-01 University Of Washington Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated
WO1995003428A1 (en) 1993-07-20 1995-02-02 University Of Massachusetts Medical Center In vivo nucleic acid hybridization method
FR2711671A1 (en) 1993-10-22 1995-05-05 Centre Nat Rech Scient Process for the detection and quantification of a nucleotide sequence in a cell population
US5660982A (en) * 1994-10-04 1997-08-26 Tryggvason; Karl Laminin chains: diagnostic uses
US5846749A (en) * 1994-10-12 1998-12-08 The Regents Of The University Of California Quantitative measurement of tissue protein identified by immunohistochemistry and standardized protein determination
US5750340A (en) 1995-04-07 1998-05-12 University Of New Mexico In situ hybridization solution and process
US6165734A (en) 1995-12-12 2000-12-26 Applied Spectral Imaging Ltd. In-situ method of analyzing cells
US6027890A (en) * 1996-01-23 2000-02-22 Rapigene, Inc. Methods and compositions for enhancing sensitivity in the analysis of biological-based assays
EP0801306A1 (en) 1996-04-10 1997-10-15 Becton, Dickinson and Company Method for immunohistochemically quantitating co-localized molecules
AU3717797A (en) 1996-07-15 1998-02-09 Children's Medical Center Corporation Method to co-detect introduced genes and their products
JP2002530678A (en) 1998-11-25 2002-09-17 バイエル コーポレイション Determination of hydride using chemiluminescent acridinium compounds

Also Published As

Publication number Publication date
US20080050748A1 (en) 2008-02-28
US7468252B2 (en) 2008-12-23
US7344840B2 (en) 2008-03-18
US6573043B1 (en) 2003-06-03
US20100120053A1 (en) 2010-05-13
WO2000020641A1 (en) 2000-04-13
US6905830B2 (en) 2005-06-14
US20030152987A1 (en) 2003-08-14
US20060183150A1 (en) 2006-08-17
US7674589B2 (en) 2010-03-09
US7919254B2 (en) 2011-04-05
US20050100944A1 (en) 2005-05-12
US20090155803A1 (en) 2009-06-18
US7129051B2 (en) 2006-10-31

Similar Documents

Publication Publication Date Title
AU6409799A (en) Tissue analysis and kits therefor
AU2245997A (en) Mutivariate sample analysis
AU1866699A (en) Biopsy instrument
AU6654898A (en) Tissue sampling device
AU5560199A (en) Adapter directed expression analysis
AU2943797A (en) Anastomosis instrument and method
AU2797499A (en) Tissue penetrating device and methods for using same
AUPN766296A0 (en) Trocar and introducing kit
AU5926699A (en) Electrosurgical biopsy device and method
AU1673100A (en) Simulated body tissue
AUPP446998A0 (en) Biopsy forceps
GB9626932D0 (en) Assay methods and kits therefor
AU6418199A (en) Multi-component process analysis and control
AU5781800A (en) Methods and compositions for assaying analytes
AU3825299A (en) Instrument for analysis and diagnostics
AU7368798A (en) Tissue analysis apparatus
AUPP662698A0 (en) Examination device
AU3453700A (en) Sample examining instrument and wiping-out examining instrument
AU2191297A (en) Blood testing kit
AU4150999A (en) Method and kit for early diagnosis of cancer
AU1914400A (en) Human hydrolase proteins
AU2587399A (en) Human transport-associated molecules
AU6110199A (en) Analysis of mixtures
AU1985200A (en) Analysis method and analyzer
AU8247598A (en) Biopsy method and device

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase